• Research Blog

    This blog has been compiled by 5 trainee paediatric gastroenterologists who are all actively involved in research into paediatric inflammatory bowel disease:

    • Dr Fiona Cameron, University of Edinburgh (CICRA fellow)
    • Dr Ed Giles, Queen Mary University of London (CICRA fellow)
    • Dr Paul Henderson, University of Edinburgh
    • Dr Tony Wiskin, University of Southampton (ex-CICRA fellow)
    • Tracy Coelho, University of Southampton

    Links are provided to the free abstracts of each article, but full access may require a fee for those without institutional privileges.

    Many thanks to Richard Hansen who has put together this blog for the last few years. He has recently started as a consultant in Glasgow so we send him our congratulations and wish him good luck in his new job. We welcome Tracy Coelho – a new CICRA fellow to the blog. He has started a PhD in Southampton to investigate how defects identified by genetic screening affect immune function.

    Latest Blog

    10.23.14 Clinical outcome in IL-10- and IL-10 receptor-deficient patients with or without hematopoietic stem cell transplantation

    In health, there is always a fine balance between the proteins that cause inflammation and the proteins that suppress inflammation. IL-10 is a key protein of the immune system of our body involved in suppressing inflammation. When an individual’s genetic make-up has severe mutations (or variations from normal) in the gene that controls IL-10, this […]

    Buty-ful: Fatty Acids Induce Tregs in the mouse gut
    How to improve response to anti-TNF drugs
    Back to Medical Stool?
    Antibiotics may increase the risk of children developing IBD
    Ciclosporin and infliximab appear equally effective in most severe form of UC
    Good bug might not be good after all in Crohn’s disease
    5-ASA drugs effective in mild to moderate Ulcerative Colitis
    Controlling inflammation in the gut – not all T cells are created equal
    1/2 of children may lose response to infliximab or adalimumab after 5 years